Literature DB >> 15362775

Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma.

Chien-Sen Tseng1, Hoi-Wan Lo, Pao-Huei Chen, Wan-Long Chuang, Chung-Chou Juan, Chen-Guo Ker.   

Abstract

BACKGROUND/AIMS: Angiogenesis and coagulation system activation are associated with tumor growth and metastasis. Vascular endothelial growth factor (VEGF) has been reported to play a major role in tumor angiogenesis. The elevation of plasma D-dimer level indicates the activation of coagulation and fibrinolysis. The purpose of this study was to: (a) evaluate the correlation between serum VEGF and plasma D-dimer level; (b) analyze the clinical features that might affect the VEGF and D-dimer levels in patients with hepatocellular carcinoma.
METHODOLOGY: Twenty patients with hepatocellular carcinoma were included prior to treatment. Serum VEGF levels were measured by enzyme-linked immunosorbent assay. Plasma D-dimer levels were measured by quantitative latex microparticle enhanced turbidimetric immunoassay.
RESULTS: The presence of a high plasma D-dimer level was found to be correlated with the presence of central necrosis, higher Child's grade, advanced TNM stage, and the presence of portal vein thrombosis when plasma D-dimer levels were compared between different clinicopathologic groups. Tumors larger than 2 cm in diameter had higher median serum VEGF levels than tumors less than 2cm in diameter. No correlation was found between plasma D-dimer level and serum VEGF level in hepatocellular carcinoma patients (r=0.126, p=0.598).
CONCLUSIONS: No correlation was found between the plasma D-dimer level and the serum VEGF level in hepatocellular carcinoma patients. The plasma D-dimer level appeared to reflect the tumor stage and vascular invasion of hepatocellular carcinoma. Serum VEGF level in hepatocellular carcinoma patients showed a positive correlation with tumor size.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362775

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Authors:  Timothy M Pawlik; Diane K Reyes; David Cosgrove; Ihab R Kamel; Nikhil Bhagat; Jean-Francois H Geschwind
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

2.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

3.  V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials.

Authors:  Ahmed O Kaseb; Manal M Hassan; E Lin; Lianchun Xiao; Vikas Kumar; Priyanka Pathak; Richard Lozano; Asif Rashid; James L Abbruzzese; Jeffrey S Morris
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

4.  Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Authors:  Manon Buijs; Diane K Reyes; Timothy M Pawlik; Amanda L Blackford; Riad Salem; Wells A Messersmith; Colin D Weekes; Mary Mulcahy; Ihab R Kamel; Jean-Francois H Geschwind
Journal:  Cancer       Date:  2012-11-06       Impact factor: 6.860

5.  Multidisciplinary management of hepatocellular carcinoma in clinical practice.

Authors:  Gemma Bruera; Katia Cannita; Aldo Victor Giordano; Rosa Manetta; Roberto Vicentini; Sergio Carducci; Patrizia Saltarelli; Nerio Iapadre; Gino Coletti; Corrado Ficorella; Enrico Ricevuto
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

6.  Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality.

Authors:  Anas A Youssef; Hisham A Issa; Maha Z Omar; Eman G Behiry; Asmaa A Elfallah; Ali Hasaneen; Mohamed Darwish; Dalia B Ibrahim
Journal:  Clin Exp Gastroenterol       Date:  2018-11-23

7.  The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).

Authors:  Wenhui Ma; Jia Jia; Shengjun Wang; Wei Bai; Jingwei Yi; Ming Bai; Zhiyong Quan; Zhanxin Yin; Daiming Fan; Jing Wang; Guohong Han
Journal:  Theranostics       Date:  2014-05-01       Impact factor: 11.556

8.  Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients.

Authors:  Mohamed Magdi El-Sadek Ali Atta; Hazem Mahmoud Atta; Magdy Abdel-Mawgoud Gad; Laila Ahmad Rashed; Ebada M Said; Sharaf El-Sayed Ali Hassanien; Ahmed O Kaseb
Journal:  J Hepatocell Carcinoma       Date:  2016-06-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.